<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC6939334/table_2" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 2</label>
  <p>Top 10 best-selling monoclonal antibody drugs in 2018</p>
 </caption>
 <thead>
  <tr>
   <th colspan="1" rowspan="1" id="0-0-.">No.</th>
   <th colspan="1" rowspan="1" id="0-1-.">Drug</th>
   <th colspan="1" rowspan="1" id="0-2-.">Indication (1st US FDA Approval Year)</th>
   <th colspan="1" rowspan="1" id="0-3-.">Company</th>
   <th colspan="1" rowspan="1" id="0-4-.">2018 Revenue (USD)</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td>1</td>
   <td>
    <p>Adalimumab</p>
    <p>(Humira)</p>
   </td>
   <td>
    <p>Rheumatoid arthritis (2002)</p>
    <p>Psoriatic arthritis (2005)</p>
    <p>Ankylosing spondylitis (2006)</p>
    <p>Juvenile Idiopathic Arthitis (2008)</p>
    <p>Psoriasis (2008)</p>
    <p>Crohn’s disease (2010)</p>
    <p>Ulcerative colitis (2012)</p>
    <p>Hidradenitis suppurativa (2015)</p>
    <p>Uveitis (2018)</p>
   </td>
   <td>AbbVie</td>
   <td>$19.9 bn</td>
  </tr>
  <tr>
   <td>2</td>
   <td>
    <p>Nivolumab</p>
    <p>(Opdivo)</p>
   </td>
   <td>
    <p>Melanoma (2015)</p>
    <p>Non-small cell lung cancer (2015)</p>
    <p>Renal cell carcinoma (2015)</p>
    <p>Head and neck squamous cell (2016)</p>
   </td>
   <td>Bristol-Myers Squibb</td>
   <td>$7.6 bn</td>
  </tr>
  <tr>
   <td>3</td>
   <td>
    <p>Pembrolizumab</p>
    <p>(Keytruda)</p>
   </td>
   <td>
    <p>Melanoma (2014)</p>
    <p>Head and neck cancer (2016)</p>
    <p>Non-small cell lung caccer (2015)</p>
    <p>Lymphoma (2018)</p>
    <p>Cervical cancer (2018)</p>
    <p>Microsatellite instability-high cancer (2018)</p>
   </td>
   <td>Merck &amp; Co</td>
   <td>$7.2 bn</td>
  </tr>
  <tr>
   <td>4</td>
   <td>
    <p>Trastuzumab</p>
    <p>(Herceptin)</p>
   </td>
   <td>
    <p>Breast cancer (1998)</p>
    <p>Gastric cancer (2010)</p>
   </td>
   <td>Roche</td>
   <td>$7.0 bn</td>
  </tr>
  <tr>
   <td>5</td>
   <td>
    <p>Bevacizumab</p>
    <p>(Avastin)</p>
   </td>
   <td>
    <p>Colorectal cancer (2004)</p>
    <p>Non-small cell lung caccer (2006)</p>
    <p>Breast ERB2 negative cancer (2008)</p>
    <p>Renal cell carcinoma (2009)</p>
    <p>Glioblastoma (2011)</p>
   </td>
   <td>Roche</td>
   <td>$6.8 bn</td>
  </tr>
  <tr>
   <td>6</td>
   <td>
    <p>Rituximab,</p>
    <p>(Rituxan)</p>
   </td>
   <td>
    <p>Non-Hodgkin’s lymphoma (1997)</p>
    <p>Chronic lymphocytic leukemia (2010)</p>
    <p>Rheumatoid arthritis (2006)</p>
    <p>Pemphigus vulgaris (2018)</p>
   </td>
   <td>Roche</td>
   <td>$6.8 bn</td>
  </tr>
  <tr>
   <td>7</td>
   <td>
    <p>Infliximab</p>
    <p>(Remicade)</p>
   </td>
   <td>
    <p>Crohn’s Disease (1998)</p>
    <p>Rheumatoid arthritis (1999)</p>
    <p>Ankylosing spondylitis (2004)</p>
    <p>Ulcerative colitis (2005)</p>
    <p>Psoriatic arthritis (2005)</p>
    <p>Psoriasis (2006)</p>
   </td>
   <td>Johnson &amp; Johnson</td>
   <td>$5.9 bn</td>
  </tr>
  <tr>
   <td>8</td>
   <td>
    <p>Ustekinumab</p>
    <p>(Stelara)</p>
   </td>
   <td>
    <p>Psoriasis (2009)</p>
    <p>Psoriatic arthritis (2013)</p>
    <p>Crohn’s Disease (2016)</p>
   </td>
   <td>Johnson &amp; Johnson</td>
   <td>$5.2 bn</td>
  </tr>
  <tr>
   <td>9</td>
   <td>
    <p>Eculizumab</p>
    <p>(Soliris)</p>
   </td>
   <td>
    <p>Paroxysmal nocturnal hemoglobinuria (2007)</p>
    <p>Atypical hemolytic uremic syndrome (2011)</p>
    <p>Generalized myasthenia gravis (2017)</p>
    <p>Neuromyelitis optica spectrum disorder (2019)</p>
   </td>
   <td>Alexion</td>
   <td>$3.6 bn</td>
  </tr>
  <tr>
   <td>10</td>
   <td>
    <p>Omalizumab</p>
    <p>(Xolair)</p>
   </td>
   <td>
    <p>Asthma (2003)</p>
    <p>Chronic idiopathic urticaria (2014)</p>
   </td>
   <td>Roche</td>
   <td>$3.0 bn</td>
  </tr>
 </tbody>
 <tfoot>
  <p>bn, billion</p>
 </tfoot>
</table>
